Home Small Molecules Discovery Biology Integrated In Vivo Pharmacology In Vivo Fibrosis Models for Drug Development
In Vivo Fibrosis Models for Drug Development
Liver, pulmonary, renal, and cardiac fibrosis. Validated disease models, advanced histopathology, mechanistic biomarkers, anti-fibrotic efficacy evaluation. Supported by in vitro and ex vivo assays.
Brief Overview on Hub:
Aragen Bioscience’s fibrosis portfolio encompasses 20+ validated preclinical models across multiple organ systems. Whether developing antifibrotic therapeutics for idiopathic pulmonary fibrosis (IPF), hepatic cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease (CKD), diabetic kidney disease (DKD), or cardiac fibrosis, our team delivers advanced histopathology, mechanistic biomarkers, and translational efficacy data supporting clinical advancement.
In Vivo Fibrosis Model Categories:
Pulmonary Fibrosis (Lung)
- Bleomycin-induced IPF (C57BL/6 mice) – acute and chronic stages
- Silica-induced lung fibrosis – occupational exposure model
- Flexible disease stage selection based on therapeutic intent
- Lung function analysis via FlexiVent
- Hypoxia assessment, bronchoalveolar lavage
Liver Fibrosis & MASH:
- Chemical-induced (CCl4, TAA) models
- Diet-induced (CDAA-HFD, AMLN-HFD, Western diet + CCl4) MASH models
- Surgical models (partial hepatectomy)
- Comprehensive fibrosis staging (F0-F4)
- Steatosis, inflammation, and fibrotic biomarkers
Renal Fibrosis
- Unilateral ureteral obstruction (UUO) – obstructive nephropathy
- 5/6 nephrectomy – chronic kidney disease (CKD)
- Diabetic kidney disease (DKD)
- Membranous nephropathy: Passive Heymann nephritis
- Repeated low dose cisplatin (RLDC) – chronic kidney disease
- Accelerated diabetic kidney disease (aDKD) models
- Glomerular sclerosis assessment
- Proteinuria and renal function markers
Cardiac Fibrosis
- Pressure overload models (TAC – transaortic constriction)
- Isoprenaline-induced cardiac fibrosis in rats
- Myocardial infarction (MI) – post-infarct remodeling
- Metabolic models (high-fat diet)
- Cardiac function assessment
- Collagen deposition and cardiomyocyte hypertrophy
Advanced Analytical Tools
- Lung function testing (FlexiVent, Oximeter, ISTAT)
- Advanced histopathology (Masson’s trichrome, Sirius red, picrosirius red)
- Gene expression profiling (fibrosis markers: Col1a1, TIMP1, MMP9, TNF-α)
- Biomarker analysis (circulating fibrosis biomarkers)
- Digital pathology with quantitative fibrosis assessment
- Imaging-based endpoints (MRI, Micro-CT)
Proven Track Record
- Established 2008, strong reputation for reproducibility
- Hundreds of studies over a decade
- Multiple IND submissions supported
- Small molecules, biologics, RNA therapeutics evaluated
- Customized model development capabilities
In Vitro & Ex Vivo Supporting Assays
- TGF-beta epithelial-mesenchymal transition (EMT) assays
- Fibroblast-to-myofibroblast transformation studies
- Co-culture assays mimicking complex tissue interactions
- Scratch wound assays with live-cell imaging (Incucyte S3)
- Precision cut lung slices (ex vivo fibrosis model)
